iCAD (NASDAQ:ICAD) Stock Crosses Above 200 Day Moving Average of $5.68
iCAD Inc (NASDAQ:ICAD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.68 and traded as high as $6.28. iCAD shares last traded at $6.27, with a volume of 538 shares changing hands.
Separately, ValuEngine downgraded iCAD from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st.
The company has a market capitalization of $122.69 million, a PE ratio of -16.50 and a beta of 1.18. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.00 and a quick ratio of 1.85. The company has a 50-day moving average of $6.46 and a two-hundred day moving average of $5.68.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ICAD. Tower Research Capital LLC TRC bought a new stake in iCAD during the second quarter valued at about $54,000. Worth Venture Partners LLC bought a new stake in iCAD during the second quarter valued at about $92,000. Deutsche Bank AG raised its holdings in iCAD by 33.5% during the fourth quarter. Deutsche Bank AG now owns 35,923 shares of the technology company’s stock valued at $132,000 after acquiring an additional 9,023 shares during the period. Spark Investment Management LLC bought a new stake in iCAD during the first quarter valued at about $185,000. Finally, Columbia Pacific Advisors LLC raised its holdings in iCAD by 218.0% during the first quarter. Columbia Pacific Advisors LLC now owns 63,600 shares of the technology company’s stock valued at $329,000 after acquiring an additional 43,600 shares during the period. Institutional investors own 19.10% of the company’s stock.
About iCAD (NASDAQ:ICAD)
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.